TABLE 3.
Summary of the Chemotherapy Regimens That Elicited a Response in Patients With Unresectable PACC
| Study, Year | Regimen | Reference |
|---|---|---|
| Brunetti et al, 2018 | GEM + oxaliplatin | 14 |
| GEM + 5-FU | ||
| FOLFIRINOX | ||
| Li et al, 2018 | Olaparib | 15 |
| Yoshihiro et al, 2017 | FOLFIRINOX | 16 |
| Yoo et al, 2017 | 5-FU + LV | 7 |
| Capecitabine (n = 2) | ||
| GEM + capecitabine | ||
| FOLFOX (n = 4) | ||
| Kruger et al, 2016 | FOLFOX (n = 2) | 13 |
| Capecitabine | ||
| FOLFIRINOX (n = 3) | ||
| GEM + oxaliplatin | ||
| GEM + erlotinib | ||
| Béchade et al, 2016 | GEM + oxaliplatin | 17 |
| Furukawa et al, 2015 | S-1 + cisplatin | 18 |
| Schempf et al, 2014 | FOLFIRINOX | 19 |
| Morales et al, 2013 | Capecitabine + oxaliplatin | 20 |
| Cananzi et al, 2013 | Docetaxel + irinotecan + cetuximab | 21 |
| Simon et al, 2012 | FOLFOX | 22 |
| Yamamoto et al, 2012 | S-1 | 23 |
| Armstrong et al, 2011 | Liposomal doxorubicin | 24 |
| Lowery et al, 2011 | GEM + oxaliplatin (n = 2) | 6 |
| GEM + cisplatin | ||
| GEM + erlotinib | ||
| GEM + docetaxel + capecitabine | ||
| Cisplatin + irinotecan | ||
| FOLFIRI | ||
| Floxuridine + irinotecan | ||
| Seki et al, 2009 | S-1 | 25 |
| Sorscher, 2009 | GEM + 5-FU + LV | 26 |
| Distler et al, 2009 | 5-FU | 27 |
| Riechelmann et al, 2003 | PTX | 28 |
| Holen et al, 2002 | 5-FU + LV + irinotecan | 12 |
| Cisplatin + cytarabine + caffeine |
FOLFIRI, 5-FU + LV + irinotecan; LV, leucovorin; PTX, paclitaxel.